Biogen Inc.
NASDAQ:BIIB · NASDAQ Global Select
-$2.21 today
Vol 1.45M · Avg 1.17M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:BIIB · Revenue to Net Income
Key Ratios
Analysis
$9.9B of revenue converted into $1.4B of net income for the selected period. Gross margin is 70.0% and net margin is 13.4%, showing how much revenue survives after costs and taxes. EPS is $9.34, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $9.8B +1.4% | $9.7B -1.6% | $9.8B -3.3% | $10.2B -7.4% | $11.0B | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $2.9B +25.4% | $2.3B -8.8% | $2.5B +11.2% | $2.3B +8.0% | $2.1B | $725.6M | $804.0M | $882.4M |
| Gross Profit | $6.9B -6.1% | $7.4B +0.9% | $7.3B -7.5% | $7.9B -11.0% | $8.9B | $8.9B | $7.6B | $6.2B |
| Gross Margin | 70.5% -5.7pp | 76.1% +1.9pp | 74.2% -3.4pp | 77.6% -3.2pp | 80.8% | 9.8% | 28.9% | 38.3% |
| Research & Development | $2.0B -21.5% | $2.5B -7.9% | $2.7B +4.1% | $2.6B -23.6% | $3.4B | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $2.4B +2.0% | $2.4B -4.6% | $2.5B +3.9% | $2.4B -10.1% | $2.7B | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $5.0B +3.3% | $4.9B -6.3% | $5.2B +4.0% | $5.0B -17.7% | $6.1B | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $935.4M +38.9% | $673.2M +36.1% | $494.8M -4.6% | $518.4M +6.3% | $487.7M | $374.2M | $1.2B | $631.8M |
| EBITDA | $3.1B +3.5% | $3.0B +26.0% | $2.4B -32.8% | $3.5B -9.9% | $3.9B | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 31.6% +0.6pp | 31.0% +6.8pp | 24.2% -10.6pp | 34.8% -1.0pp | 35.7% | 5.6% | 46.3% | 42.0% |
| Operating Income | $1.9B -24.6% | $2.5B +18.7% | $2.1B -27.4% | $2.9B +3.5% | $2.8B | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 19.1% -6.6pp | 25.7% +4.4pp | 21.3% -7.1pp | 28.4% +3.0pp | 25.4% | 16.6% | 24.1% | 22.0% |
| Interest Income | $87.8M +29.9% | $67.6M -75.6% | $276.5M +209.6% | $89.3M +711.8% | $11.0M | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $246.0M -1.7% | $250.3M +1.4% | $246.9M +0.1% | $246.6M -2.8% | $253.6M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$476.0M +18.5% | -$584.3M +27.0% | -$800.5M -213.5% | $705.3M +169.7% | -$1.0B | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $1.4B -26.5% | $1.9B +47.0% | $1.3B -63.9% | $3.6B +101.9% | $1.8B | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 14.3% -5.4pp | 19.7% +6.5pp | 13.2% -22.1pp | 35.3% +19.1pp | 16.2% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $108.1M -60.5% | $273.8M +102.4% | $135.3M -78.6% | $632.8M +1105.3% | $52.5M | $1.3B | -$1.6B | $745.2M |
| Net Income | $1.3B -20.8% | $1.6B +40.6% | $1.2B -61.9% | $3.0B +95.8% | $1.6B | $4.9B | $4.8B | $4.7B |
| Net Margin | 13.2% -3.7pp | 16.9% +5.1pp | 11.8% -18.1pp | 29.9% +15.8pp | 14.2% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $9 -21.0% | $11 +39.7% | $8 -61.8% | $21 +100.9% | $10 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $9 -21.1% | $11 +40.4% | $8 -61.8% | $21 +100.7% | $10 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $146.7M +0.7% | $145.7M +0.7% | $144.7M -0.4% | $145.3M -2.5% | $149.1M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $146.7M +0.5% | $145.9M +0.2% | $145.6M -0.3% | $146.0M -2.4% | $149.6M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Teva Pharmaceutical Industries Limited
NYSE:TEVA
$36.63B
DexCom, Inc.
NASDAQ:DXCM
$27.85B
Waters Corporation
NYSE:WAT
$23.19B
United Therapeutics Corporation
NASDAQ:UTHR
$22.95B
Quest Diagnostics Incorporated
NYSE:DGX
$21.49B
Labcorp Holdings Inc.
NYSE:LH
$20.95B
STERIS plc
NYSE:STE
$19.66B
Incyte Corporation
NASDAQ:INCY
$19.53B
Genmab A/S
NASDAQ:GMAB
$15.54B
Insulet Corporation
NASDAQ:PODD
$10.01B
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does BIIB generate?
Biogen Inc. (BIIB) reported $9.81B of revenue in fiscal 2025.
Is BIIB profitable?
Biogen Inc. (BIIB) reported $1.29B of net income, with a net margin of 13.2%.
Explore More
Continue the stock analysis
Jump to another research area for this company.